Kymriah (tisagenlecleucel, CTL-019, Novartis AG) and other chimeric antigen receptor (CAR) T cells have been making their way through clinical trials as cell therapies. So the FDA’s Aug. 30 announcement that its approval of Kymriah was “a historic action today making the first gene therapy available in the United States” initially led to some head-scratching.